Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Protego Biopharma, Inc.

Protego Biopharma, Inc.

Series BSan Diego, CAOther Health Care
Facts
Year of incorporation
unknown
Revenue range (Form D)
Decline to Disclosesec.gov
Rounds on record
2
Disclosed raised
$130Msum of rounds with a disclosed amount only
Named investors
8
Financing history
2 rounds
  1. Dec 1, 2025
    Series B · $130M (disclosed)
    Novartis Venture Fund (lead)Forbion (lead)Droia Ventures (participant)YK Bioventures (participant)MPM Bioimpact (participant)Lightspeed Venture Partners (participant)Chris Weyrer (participant)Vida Ventures Advisors (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Protego Biopharma Raises $130 Million Oversubscribed Series B Financing to Advance First-in-Class AL Amyloidosis Program into Pivotal Study”
  2. Oct 17, 2025
    Form D equity offering · $32.9M (form d sold) · 18 investors
    Fact SEC EDGAR Form D data sets (quarterly) · “Protego Biopharma, Inc. filed Form D: $32,942,190 sold of $130,442,180, Other Health Care”
Investors on record
8 edges
People
2 officers, 8 directors
Timeline
2
  1. Dec 3, 2025
    Protego Biopharma, Inc. filed Form D: $32,942,190 sold of $130,442,180, Other Health Care
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
  2. Dec 1, 2025
    Protego Biopharma announced Series B of $130,000,000, led by Novartis Venture Fund, Forbion
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
15 observations
Every observation on this company